Peptide-Based Imaging and Therapy Targets Rare Lung Metastases from Brain Tumor
A rare case of meningioma lung metastases was detected using peptide-based PET/CT imaging and successfully treated with peptide receptor radionuclide therapy (PRRT).
Quick Facts
What This Study Found
Refractory meningioma with lung metastases showed high somatostatin receptor expression on 68Ga-DOTATOC PET/CT, enabling successful targeted treatment with 177Lu-DOTATATE peptide receptor radionuclide therapy.
Key Numbers
How They Did This
Single case report of a meningioma patient with lung metastases diagnosed by 68Ga-DOTATOC PET/CT and treated with 177Lu-DOTATATE PRRT.
Why This Research Matters
Demonstrates that peptide-based theranostics (combined diagnosis and therapy) can manage rare metastatic meningiomas that fail conventional treatments.
The Bigger Picture
This case illustrates the growing power of peptide-based theranostics — using the same molecular target for both diagnosis and treatment — which is revolutionizing cancer care beyond neuroendocrine tumors.
What This Study Doesn't Tell Us
Single case report — cannot be generalized. Not all meningiomas express somatostatin receptors at levels sufficient for PRRT.
Questions This Raises
- ?Should all refractory meningiomas be screened for SSTR expression using DOTA-peptide PET/CT?
- ?How durable are PRRT responses in metastatic meningioma?
Trust & Context
- Key Stat:
- Theranostic success Same peptide target (SSTR) used for both diagnosis and treatment of metastatic meningioma
- Evidence Grade:
- Single case report — lowest level of clinical evidence but demonstrates proof of concept for an uncommon clinical scenario.
- Study Age:
- Published in 2026; reflects current availability of DOTA-peptide imaging and PRRT.
- Original Title:
- Lung Metastases from Meningioma Diagnosed on Whole Body 68Ga-DOTATOC PET/CT and Successfully Targeted With 177Lu-DOTATATE.
- Published In:
- Clinical nuclear medicine, 51(4), 335-337 (2026)
- Database ID:
- RPEP-14857
Evidence Hierarchy
Frequently Asked Questions
What is PRRT?
Peptide receptor radionuclide therapy (PRRT) uses radioactive peptides that bind to specific receptors on tumor cells, delivering targeted radiation directly to the cancer while minimizing damage to healthy tissue.
Can brain tumors spread to the lungs?
Meningioma metastasis is very rare, but it can happen with aggressive (WHO grade II-III) tumors. The lungs are the most common site for meningioma metastases when they do occur.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14857APA
Bekkhoucha, Adam; Agrigoroaie, Laurentiu; Deandreis, Desiree; Guyon, David; Chehade, Feras. (2026). Lung Metastases from Meningioma Diagnosed on Whole Body 68Ga-DOTATOC PET/CT and Successfully Targeted With 177Lu-DOTATATE.. Clinical nuclear medicine, 51(4), 335-337. https://doi.org/10.1097/RLU.0000000000006352
MLA
Bekkhoucha, Adam, et al. "Lung Metastases from Meningioma Diagnosed on Whole Body 68Ga-DOTATOC PET/CT and Successfully Targeted With 177Lu-DOTATATE.." Clinical nuclear medicine, 2026. https://doi.org/10.1097/RLU.0000000000006352
RethinkPeptides
RethinkPeptides Research Database. "Lung Metastases from Meningioma Diagnosed on Whole Body 68Ga..." RPEP-14857. Retrieved from https://rethinkpeptides.com/research/bekkhoucha-2026-lung-metastases-from-meningioma
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.